The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity

Saved in:
Bibliographic Details
Published inMolecular immunology Vol. 47; no. 13; p. 2215
Main Authors Risitano, Antonio M., Pascariello, Caterina, Selleri, Carmine, Del Vecchio, Luigi, Sica, Michela, Fridkis-Hareli, Masha, Mazsaroff, Istvan, Horvath, Christopher J., Holers, V. Michael
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.08.2010
Online AccessGet full text

Cover

More Information
ISSN:0161-5890
1872-9142
DOI:10.1016/j.molimm.2010.05.059